Borderline leprosy: Difference between revisions
CSV import |
CSV import |
||
| Line 36: | Line 36: | ||
[[Category:Neurology]] | [[Category:Neurology]] | ||
{{medicine-stub}} | {{medicine-stub}} | ||
{{No image}} | |||
Revision as of 08:00, 10 February 2025
Borderline Leprosy is a form of leprosy, a chronic infectious disease caused by Mycobacterium leprae. This form of leprosy is characterized by skin lesions that are more numerous than in tuberculoid leprosy, but less so than in lepromatous leprosy.
Etiology
Borderline leprosy is caused by Mycobacterium leprae, a slow-growing bacterium that primarily affects the skin and nerves. The exact mode of transmission is not fully understood, but it is believed to occur through respiratory droplets or direct contact with nasal and oral secretions from an infected person.
Clinical Features
Patients with borderline leprosy typically present with numerous skin lesions that can be either hypo- or hyper-pigmented. The lesions may be asymmetric and have a raised, erythematous border. Nerve involvement is common, leading to sensory and motor deficits.
Diagnosis
Diagnosis of borderline leprosy is primarily based on clinical findings. Skin biopsy and skin smear tests can be used to confirm the diagnosis. The Ridley-Jopling scale is often used to classify the disease.
Treatment
Treatment for borderline leprosy typically involves a multi-drug therapy consisting of dapsone, rifampicin, and clofazimine. Early diagnosis and treatment are crucial to prevent nerve damage and disability.
Epidemiology
Borderline leprosy is more common in areas with high prevalence of leprosy, such as India, Brazil, and parts of Africa. It can affect individuals of any age, but is more common in adults.
See Also
References
<references group="" responsive="1"></references>
